MicroRNA as Markers in Testicular Cancer

Recruiting now

Conditions studied: Testicular Germ Cell Cancer, Seminoma, Non-Seminoma Testicular Cancer, Stage I Testicular Cancer, Stage II Testicular Cancer, Stage III Testicular Cancer, Stage IV Testicular Cancer, Relapse Testicular Cancer

In brief

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Key facts

Study ID

NCT04914026

Run by

Haukeland University Hospital

People needed

350

Starts

2016-12-31

Expected to finish

2026-12-31

Last updated by the study team

2022-08-08

Who can join

Age: 18 and older, up to 70. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with suspected testicular cancer, referred to orchiectomy.
• Patients diagnosed with testicular germ cell cancer.
• Age 18-70 years of age.
• Must be able receive information and to consent.

You may not qualify if…

• Other prior or concomitant malignancy (other than testicular cancer).
• Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.

Where it is running

• Haukeland University Hospital — Bergen, Norway (enrolling)
• Haugesund Hospital — Haugesund, Norway (enrolling)
• University Hospital of North Norway — Tromsø, Norway (enrolling)
• Karolinska University Hospital — Stockholm, Sweden (enrolling)
• Oslo University Hospital — Oslo, Norway
• Sahlgrenska University Hospital — Gothenburg, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.